A path to translation: How 3D patient tumor avatars enable next generation precision oncology

doi:10.1016/j.ccell.2022.09.017

A path to translation: How 3D patient tumor avatars enable next generation precision oncology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

Original language	English
Pages (from-to)	1448-1453
Number of pages	6
Journal	Cancer Cell
Volume	40
Issue number	12
DOIs	https://doi.org/10.1016/j.ccell.2022.09.017
Publication status	Published - 12 Dec 2022

Access to Document

10.1016/j.ccell.2022.09.017

1-s2.0-S1535610822004755-mainFinal published version, 998 KBLicence: Taverne

Cite this

@article{2918c809c33a40f285b1d4e1788b1daa,

title = "A path to translation: How 3D patient tumor avatars enable next generation precision oncology",

abstract = "3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.",

author = "Margarida Barroso and Chheda, \{Milan G.\} and Hans Clevers and Elena Elez and Salma Kaochar and Kopetz, \{Scott E.\} and Li, \{Xiao Nan\} and Funda Meric-Bernstam and Meyer, \{Clifford A.\} and Haiwei Mou and Naegle, \{Kristen M.\} and Pera, \{Martin F.\} and Zinaida Perova and Politi, \{Katerina A.\} and Raphael, \{Benjamin J.\} and Paul Robson and Sears, \{Rosalie C.\} and Josep Tabernero and Tuveson, \{David A.\} and Welm, \{Alana L.\} and Welm, \{Bryan E.\} and Willey, \{Christopher D.\} and Konstantin Salnikow and Chuang, \{Jeffrey H.\} and Xiling Shen",

note = "Funding Information: We thank the NCI 3D Workshop, Patient-Derived Model of Cancer (PDMC) Program, and PDXNet for constructive discussions, recommendations, and purposeful efforts to advance the practice of precision oncology. This work was supported by National Cancer Institute grants NIH-U01CA217514 and U01CA214300 as well as National Institutes of Health F30 fellowship 1F30CA257365-01 . Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = dec,

day = "12",

doi = "10.1016/j.ccell.2022.09.017",

language = "English",

volume = "40",

pages = "1448--1453",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - A path to translation

T2 - How 3D patient tumor avatars enable next generation precision oncology

AU - Barroso, Margarida

AU - Chheda, Milan G.

AU - Clevers, Hans

AU - Elez, Elena

AU - Kaochar, Salma

AU - Kopetz, Scott E.

AU - Li, Xiao Nan

AU - Meric-Bernstam, Funda

AU - Meyer, Clifford A.

AU - Mou, Haiwei

AU - Naegle, Kristen M.

AU - Pera, Martin F.

AU - Perova, Zinaida

AU - Politi, Katerina A.

AU - Raphael, Benjamin J.

AU - Robson, Paul

AU - Sears, Rosalie C.

AU - Tabernero, Josep

AU - Tuveson, David A.

AU - Welm, Alana L.

AU - Welm, Bryan E.

AU - Willey, Christopher D.

AU - Salnikow, Konstantin

AU - Chuang, Jeffrey H.

AU - Shen, Xiling

N1 - Funding Information: We thank the NCI 3D Workshop, Patient-Derived Model of Cancer (PDMC) Program, and PDXNet for constructive discussions, recommendations, and purposeful efforts to advance the practice of precision oncology. This work was supported by National Cancer Institute grants NIH-U01CA217514 and U01CA214300 as well as National Institutes of Health F30 fellowship 1F30CA257365-01 . Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/12/12

Y1 - 2022/12/12

N2 - 3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

AB - 3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

UR - https://www.scopus.com/pages/publications/85145839383

U2 - 10.1016/j.ccell.2022.09.017

DO - 10.1016/j.ccell.2022.09.017

M3 - Comment/Letter to the editor

AN - SCOPUS:85145839383

SN - 1535-6108

VL - 40

SP - 1448

EP - 1453

JO - Cancer Cell

JF - Cancer Cell

IS - 12

ER -

A path to translation: How 3D patient tumor avatars enable next generation precision oncology

Abstract

Access to Document

Other files and links

Fingerprint

Cite this